Immucell Cp Down 5.35% To $4.60 After Earnings

Friday, May 12, 2023 - Immucell Cp (ICCC) reported downside earnings and upside revenues.

The company reported an EPS loss of $0.30 per share. The firm reported an EPS of $0.07 in the year-ago quarter. The decline in Immucell Cp's annual growth rate represents how the business isn't performing well amid current economic conditions.

Immucell Cp Q1 2023 revenue came in at $3.4 million. The company achieved negative 43% growth year-over-year compared to the firm's revenue of $6 million from the year-ago quarter. The lower earnings growth relative to revenue signals Immucell Cp has not been able to improve its profit margin.

The stock is down 5.35% to $4.60 after the report.

Immucell Cp's profit margins took a hit as earnings fell at a faster pace than revenues.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 12.

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. The company generates the majority of its revenue from the United States.